


**LISTING OF THE CLAIMS**

The following is a complete listing of the claims with a status identifier in parentheses.

LISTING OF THE CLAIMS

1. (PREVIOUSLY PRESENTED) A compound of the following general formula (I):



(I)

wherein

$R_2$  designates hydrogen, Me, Et, CHO, CN, OH, OMe,  $COR_9$ ,  $COOR_9$ ,  $CONHR_9$  or  $CSNHR_9$ , whereby  $R_9$  denotes  $(C_1-C_4)$  alkyl;

$R_5$  designates hydrogen,  $(C_1-C_4)$  alkyl, OH,  $(C_1-C_4)$  alkoxy,  $OCF_3$ , trifluoromethyl or halogen;

$R_6$  designates Me,  $(C_1-C_4)$  alkoxy,  $OCF_3$ , SMe or SEt;

n is 1 or 2;

R<sub>3</sub>' and R<sub>5</sub>' each independently designate OH, Me, Et, OMe, OCF<sub>3</sub>, trifluoromethyl or halogen;

U designates N or CR<sub>2</sub>', whereby R<sub>2</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, trifluoromethyl or halogen;

V designates N or CR<sub>4</sub>', whereby R<sub>4</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>6</sub>) alkoxy, (C<sub>1</sub>-C<sub>6</sub>) alkyl, OH, trifluoromethyl or halogen;

W designates N or CR<sub>6</sub>', whereby R<sub>6</sub>' denotes hydrogen, (C<sub>1</sub>-C<sub>4</sub>) alkyl, (C<sub>1</sub>-C<sub>4</sub>) alkoxy, trifluoromethyl or halogen; and pharmaceutically acceptable salts thereof.

2. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>2</sub> designates Me, OH, CN, CHO, COR<sub>9</sub> or COOR<sub>9</sub>.

3. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>2</sub> designates Me, CN, CHO or COMe.

4. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>5</sub> designates hydrogen, Me, OMe or halogen.

5. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>6</sub> designates OMe or OEt.

6. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>5</sub> designates hydrogen or OMe, preferably hydrogen; and R<sub>6</sub> designates OMe.
7. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>3</sub>' and R<sub>5</sub>' each independently designate chloro, bromo, Me or OMe.
8. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein R<sub>3</sub>' and R<sub>5</sub>' are identical; or R<sub>3</sub>' designates chloro or bromo, and R<sub>5</sub>' designates OMe.
9. (PREVIOUSLY PRESENTED) A compound according to claim 7, wherein R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.
10. (PREVIOUSLY PRESENTED) A compound according to claim 1, wherein U and W designate CH and V designates CR<sub>4</sub>'.
11. (PREVIOUSLY PRESENTED) A compound according to claim 10, wherein R<sub>4</sub>' designates hydrogen, chloro, bromo, Me or OMe.
12. (PREVIOUSLY PRESENTED) A compound according to claim 10, wherein R<sub>3</sub>', R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>3</sub>' designates chloro and R<sub>4</sub>' and R<sub>5</sub>' designate OMe; or R<sub>4</sub>' designates hydrogen and R<sub>3</sub>' and R<sub>5</sub>' designate both chloro or both bromo.

13. (PREVIOUSLY PRESENTED) A compound according to claim 1, which is 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-

ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-

(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline      1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline,      1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline    or    1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, or a pharmaceutically acceptable salt thereof.

14. (PREVIOUSLY PRESENTED) A compound according to claim 1, which is the (R) - or (S)-enantiomer.

15. (PREVIOUSLY PRESENTED) A compound as defined in claim 1, for use as a medicament.

16. (PREVIOUSLY PRESENTED) Use of a compound as defined in claim 1, for the preparation of a medicament for the prophylaxis or treatment of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial.

17. (PREVIOUSLY PRESENTED) The use according to claim 16, wherein the disease is selected from cell proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases such as psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

18. (PREVIOUSLY PRESENTED) A method of treatment or prophylaxis of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, in a subject in need of such treatment or prophylaxis, comprising administering to said subject an amount of a compound (I) as defined in claim 1 in an amount which is effective in down-regulating or inhibiting the expression or function of the IGF-1 receptor.

19. (PREVIOUSLY PRESENTED) The method of claim 18, wherein the disease is selected from cell proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases such as psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

20. (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof as defined in claim 1, and a pharmaceutically acceptable adjuvant, diluent or carrier.

21. (PREVIOUSLY PRESENTED) Articles containing a compound of the formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1, and a chemotherapeutic agent, as a combination for the simultaneous, separate or successive administration in the therapy of a disease in which down-

regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial.

22. (PREVIOUSLY PRESENTED) Use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1, as a pharmacological tool in the development and standardization of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals.

\* \* \* \* \*

END OF CLAIM LISTING

THE REMAINDER OF THE PAGE HAS BEEN LEFT BLANK INTENTIONALLY